HDAC6-IN-42

HDAC6-IN-42 产品活性：HDAC6-IN-42 (compound 2b) 作为一种 HDAC6 抑制剂 (IC50=0.009 μM)，展现出了显著的抗白血病活性和与 Decitabine (HY-A0004) 的协同效应，这表明它可用于 Acute Myeloid Leukemia (AML) 的研究。 产品来源： www.medchemexpress.cn/hdac6-in-42.html 研究领域：Cell Cycle/DNA Damage | Epigenetics 作用靶点：HDAC In Vitro: HDAC6-IN-42 increases in antiproliferative activity against the three leukemia cell lines (HAL01: 2.32±0.77 μM, HL60: 2.04±0.62 μM, Jurkat: 3.08±0.59 μM) which is more than five times higher than HPOB. HDAC6-IN-42 shows even higher selectivity for HDAC6 against HDAC2 (IC50=0.787 μM; SIHDAC2/6=87) and HDAC3 (IC50= 0.520 μM; SIHDAC3/6=58) compared to HDAC1 (IC50=0.228 μM; SIHDAC1/6=25). HDAC6-IN-42 (1, 5 μM; 48 h) exhibits any cytotoxic activity against healthy fibroblasts and exhibits a significant increase in the percentage of late apoptotic cells. HDAC6-IN-42 excels significantly in inducing specific drug synergy with Decitabine (HY-A0004) against AML cells. 相关产品：Trichostatin A | Vorinostat | 4-Phenylbutyric acid | Valproic acid | Sulforaphane | Panobinostat | Entinostat | Romidepsin | Tucidinostat | RGFP966 | Belinostat | Tubastatin A | Ricolinostat | TMP195 | Carbamazepine | Mocetinostat | ITSA-1 | Tasquinimod | Theophylline | Santacruzamate A | LMK-235 | TMP269 | Quisinostat | Tubacin | Fimepinostat | PCI-34051 | FT895 | Pyroxamide 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。